S&P 500   3,924.82 (-0.42%)
DOW   33,524.48 (-0.21%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
S&P 500   3,924.82 (-0.42%)
DOW   33,524.48 (-0.21%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
S&P 500   3,924.82 (-0.42%)
DOW   33,524.48 (-0.21%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
S&P 500   3,924.82 (-0.42%)
DOW   33,524.48 (-0.21%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
NASDAQ:BVXV

BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

$9.95
+0.14 (+1.43%)
(As of 12/7/2022 10:45 AM ET)
Add
Compare
Today's Range
$9.95
$9.95
50-Day Range
$5.50
$10.00
52-Week Range
$5.34
$34.90
Volume
750 shs
Average Volume
10,021 shs
Market Capitalization
$14.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00

BiondVax Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
603.5% Upside
$70.00 Price Target
Short Interest
Healthy
1.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of BiondVax Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

599th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

99th out of 171 stocks

BVXV stock logo

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

BiondVax Announces Plan to Implement ADS Ratio Change
BiondVax provides plan to address Nasdaq compliance
BiondVax's Strategic Research Collaboration...
BVXV_t5 Historical Data
BVXV: Significant Progress Made in NanoAb Program…
Biondvax Pharmaceuticals reports Q1 results
BiondVax Pharma Reports Q1 Results
See More Headlines
Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Company Calendar

Last Earnings
3/28/2022
Today
12/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BVXV
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+603.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-12,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.23 per share

Miscellaneous

Free Float
1,347,000
Market Cap
$14.23 million
Optionable
Not Optionable
Beta
2.43

Key Executives

  • Mr. Amir Reichman M.B.A. (Age 46)
    M.Sc., CEO & Director
  • Mr. Uri Ben-Or CPA (Age 52)
    CPA, M.B.A., MBA, Chief Financial Officer
  • Mr. Elad Mark B.Sc. (Age 40)
    Eng., M.B.A., Chief Operating Officer
  • Dr. Tamar Ben-Yedidia Ph.D. (Age 58)
    Chief Scientist
  • Mr. Joshua E. Phillipson B.Sc.
    M.B.A., Director of Bus. Devel. & Investor Relations
  • Ms. Moran Ahdout Fruchter L.L.B.
    Chief of Staff
  • Ms. Dalit Weinstein Fischer
    Head of Technical R&D













BVXV Stock - Frequently Asked Questions

Should I buy or sell BiondVax Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BVXV shares.
View BVXV analyst ratings
or view top-rated stocks.

What is BiondVax Pharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month target prices for BiondVax Pharmaceuticals' shares. Their BVXV share price forecasts range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 613.6% from the stock's current price.
View analysts price targets for BVXV
or view top-rated stocks among Wall Street analysts.

How have BVXV shares performed in 2022?

BiondVax Pharmaceuticals' stock was trading at $23.50 at the beginning of the year. Since then, BVXV stock has decreased by 58.3% and is now trading at $9.81.
View the best growth stocks for 2022 here
.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 32,700 shares, a decrease of 86.9% from the October 31st total of 250,400 shares. Based on an average daily volume of 7,700 shares, the days-to-cover ratio is currently 4.2 days. Currently, 1.8% of the shares of the stock are short sold.
View BiondVax Pharmaceuticals' Short Interest
.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80.

When did BiondVax Pharmaceuticals' stock split?

Shares of BiondVax Pharmaceuticals reverse split on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

Who are BiondVax Pharmaceuticals' major shareholders?

BiondVax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.55%).

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $9.81.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $14.06 million. The company earns $-12,850,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 12/7/2022 by MarketBeat.com Staff